fig1

Figure 1. Approach to stem cell mobilization in newly diagnosed multiple myeloma. CXCR4: Chemokine receptor type 4; Dara: daratumumab; DRD: daratumumab -lenalidomide-dexamethasone; G-CSF: granulocyte colony-stimulating factor; KRD: carfilzomib-lenalidomide-dexamethasone; PR: partial response; RVD: lenalidomide- bortezomib-dexamethasone; Vel: bortezomib.